0.493

13.54% 0.0588

Actuate Therapeutics Inc (ACTU)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.4342

Offen:

$0.457

24-Stunden-Volumen:

337.75K

Relative Volume:

0.83

Marktkapitalisierung:

$11.84M

Einnahmen:

Nettoeinkommen (Verlust:

$-21.54M

KGV:

-0.4978

EPS:

-0.9904

Netto-Cashflow:

$-19.60M

1W Leistung:

-27.39%

1M Leistung:

-49.88%

6M Leistung:

-77.07%

1J Leistung:

-93.70%

1-Tages-Spanne:

$0.4326

$0.4987

1-Wochen-Bereich:

$0.41

$0.6801

52-Wochen-Spanne:

$0.41

$8.2652

Actuate Therapeutics Inc Stock (ACTU) Company Profile

Firmenname

Actuate Therapeutics Inc

Sektor

Healthcare (1051)

Branche

Biotechnology (593)

Telefon

847-986-4190

Adresse

1751 RIVER RUN, FORT WORTH

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-11-12

Neueste SEC-Einreichungen

ACTU's Discussions on Twitter

Compare ACTU vs VRTX, MRNA, REGN, ARGX, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACTU Actuate Therapeutics Inc	0.493	11.84M	0	-21.54M	-19.60M	-0.9904
VRTX Vertex Pharmaceuticals Inc	508.15	128.80B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	238.82	95.35B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	799.63	82.33B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.39	53.54B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	373.90	42.30B	5.76B	514.49M	1.10B	4.4813

Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-26	Eingeleitet	B. Riley Securities	Buy
2025-04-22	Eingeleitet	Craig Hallum	Buy
2025-03-17	Eingeleitet	H.C. Wainwright	Buy

Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten

Oct 08, 2026

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research

Oct 08, 2026

Oct 06, 2026

Actuate Therapeutics to sell 50 million shares at assumed $0.819 price - scanx.trade

Oct 06, 2026

Actuate Therapeutics Registers 50 Million Shares for Public Offering at $0.819 Each - Kalkine Media

Oct 06, 2026

At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering. - Stock Titan

Oct 06, 2026

Sep 17, 2026

Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Stock Quote - The Chronicle-Journal

Sep 17, 2026

Sep 09, 2026

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire

Sep 09, 2026

Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models - Quiver Quantitative

Sep 09, 2026

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance

Sep 09, 2026

Sep 02, 2026

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance

Sep 02, 2026

Aug 21, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm

Aug 21, 2026

Aug 20, 2026

Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionInvestor Earnings Call - vinanet.vn

Aug 20, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseRevenue Estimate Trend - vinanet.vn

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - careplusvn.com

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseEarnings Recovery Stocks - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseSurprise Factor Analysis - dars.gov.et

Aug 20, 2026

Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionEarnings Revision Downgrade - https://www.dars.gov.et/

Aug 20, 2026

Aug 18, 2026

Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceBullish Percent Index - vinanet.vn

Aug 18, 2026

Actuate Therapeutics stock gets FDA clearance for elraglusib trial By Investing.com - Investing.com Canada

Aug 18, 2026

Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceInverse ETF Flow - dars.gov.et

Aug 18, 2026

Aug 16, 2026

Actuate Therapeutics (ACTU) Gains 3.58% to $1.01, Approaches Key Resistance at $1.06Bullish Pattern Stocks - vinanet.vn

Aug 16, 2026